Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

Vaccine

Volumn 14, Issue 16, 1996, Pages 1523-1530

  Nixon, Douglas F ^b   Hioe, Catarina ^c   Chen, Pei De ^a   Bian, Zuning ^a   Kuebler, Peter ^d   Li, Ming Lie ^a   Qiu, Howard ^a   Li, Xuan Mao ^a   Singh, Manmohan ^a   Richardson, Julie ^e   McGee, Paul ^f   Zamb, Tim ^a   Koff, Wayne ^a   Wang, Chang Yi ^a   O'Hagan, Derek ^g  

^a United Biomedical Inc   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Sunshine Health Center   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f Cor Technologies Ltd ^*  (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CTL; Lipopeptides; Microparticles; Peptides; Vaccines

Indexed keywords

LIPOPEPTIDE; PARASITE ANTIGEN; SYNTHETIC PEPTIDE; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; ANTIGENS, VIRAL; EMULSIONS; FEMALE; INFLUENZA A VIRUS; LACTIC ACID; LIPOPROTEINS; MICE; MICE, INBRED BALB C; MICROSPHERES; PEPTIDES; PLASMODIUM BERGHEI; POLYGLYCOLIC ACID; POLYMERS; SOYBEANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0001552479     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00099-0     Document Type: Article

References (21)

1. 1 Kast, W.M., Roux, L., Curren, J. et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA. 1991, 88, 2283-2287
2. 2 Romero, P., Maryanski, J.L., Cordey, A.-S., Corradin, G., Nussenzweig, R.S., Zavala, F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341, 323-326
3. 3 Feltkamp, M.C.W., Smits, H.L., Vierboom, M.P.M. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 1993, 23, 2242-2249
4. 4 Deres, K. Schild, H-J., Wiesmuller, K-H., Jung, G. and Rammensee H-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989, 342, 561-564
5. 5 Martinon, F., Gras-Masse, H., Boutillon, C. et al. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. J. Immunol. 1992, 149, 3416-3422
6. 6 Vitiello, A., Ishioka, G., Grey, H.M. et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest. 1995, 95, 341-349
7. 7 Borges, B., Wiesmöller, K.-H., Jung, G. and Walden, P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J. Immunol. Methods. 1994, 173, 253-263
8. 8 Lipford, G.B., Wagner, H. and Heeg, K. Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine. 1994, 12, 73-80
9. 9 Zhou, F., Rouse, B.T. and Huang, L. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol. 1992, 149, 599-604
10. 10 Aichele, P., Hengartner, H., Zinkernagel, R.M. and Schulz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 1990, 171, 1815-1820
11. 11 Layton, G.T., Harris, S.J., Gearing, A.J.H., Griffiths, J.C., Burns, N.R., Adams, S.E. and Kingsman A.J. HIV-1 V3 loop-specific CTLs are primed in vivo using hybrid V3:Ty-VLPs. In: Vaccines 93: Modern approaches to new vaccines including prevention of AIDS, (Eds Ginsberg, H.S., Brown, F., Chanock, R.M. and Lerner, R.A.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1993, pp. 85-90
12. 12 Maloy, K.J., Donachie, A.M., O'Hagan, D.T. and Mowat, A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-coglycolide) microparticles. Immunology 1994, 81, 661-667
13. 13 O'Hagan, D.T., Jeffery, H. and Davis, S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11, 965-969
14. 14 O'Hagan, D.T., McGee, J.P., Holmgren, J. et al. Biodegradable microparticles for oral immunization. Vaccine 1993, 11, 149-154
15. 15 Alonso, M.J., Gupta, R.K., Min, C., Siber, G.R. and Langer, R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12, 299-306
16. d molecule affect CTL recognition and binding of the nucleoprotein peptide from lymphocytic choriomeningitis virus. Immunogenetics 1994, 40, 222-229
17. 17 Claassen, I.J.T.M., Osterhaus, A.D.M.E. and Claassen, E. Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen: involvement of marginal metallophilic macrophages in the uptake of immune-stimulating complexes. Eur. J. Immunol. 1995, 25, 1446-1452
18. 18 Hioe C, Qiu H, Chen P et al. Comparison of adjuvant formulations for CTL induction using synthetic peptides. Vaccine, 1996, 14, 412-418
19. 19 Visscher, G.E., Robison, R.L. and Argentieri, G.I. Tissue response to biodegradable injectable microcapsules. J. Biomat. Appl. 1987, 2, 118
20. 20 Wise, D.L., Fellman, T.D., Sanderson, J.E. and Wentworth, R.L. Lactide/glycolide polymers. Description of the polymers used as surgical suture material, raw material for osteosynthesis and in sustained release forms of drugs. In: Drug carriers in Medicine, Academic Press, London, 1987, p. 237
21. 21 Maulding, H.V. Prolonged delivery of peptides by microcapsules. J. Cont. Rel. 1987, 6, 167